Abstract

Introduction: The use of opioids in mastectomy patients is a particular challenge, having to balance the management of acute pain while minimizing risks of continuous opioid use postoperatively. Despite attempts to decrease postmastectomy opioid use, including regional anesthetics, gabapentinoids, topical anesthetics, and nonopioid anesthesia, prolonged opioid use remains clinically significant among these patients. The goal of this study is to identify risk factors and develop machine-learning-based models to predict patients who are at higher risk for postoperative opioid use after mastectomy.Methods: In this retrospective cohort study, we collected data from patients that underwent mastectomy procedures. The primary outcome of interest was defined as oxycodone milligram equivalents (OME) greater than or equal to the 75% of OME use on a postoperative day 1. Model performance (area under the receiver-operating characteristics curve (AUC)) of various machine learning approaches was calculated via 10-fold cross-validation. Odds ratio (OR) and 95% confidence intervals (CI) were reported.Results: There were a total of 148 patients that underwent mastectomy and were included. The medium (quartiles) postoperative day 1 opioid use was 5 mg OME (0.25 mg OME). Using multivariable logistic regression, the most protective factors against higher opioid use was being postmenopausal (OR: 0.13, 95% CI: 0.03-0.61, p = 0.009) and cancer diagnosis (OR: 0.19, 95% CI: 0.05-0.73, p = 0.01). The AUC was 0.725 (95% CI: 0.572-0.876). There was no difference in the performance of other machine-learning-based approaches.Conclusions: The ability to predict patients’ postoperative pain could have a significant impact on preoperative counseling and patient satisfaction.

Highlights

  • The use of opioids in mastectomy patients is a particular challenge, having to balance the management of acute pain while minimizing risks of continuous opioid use postoperatively

  • The most protective factors against higher opioid use was being postmenopausal (OR: 0.13, 95% confidence intervals (CI): 0.03-0.61, p = 0.009) and cancer diagnosis (OR: 0.19, 95% CI: 0.05-0.73, p = 0.01)

  • Postmastectomy pain syndrome (PMPS) is a type of chronic neuropathic pain disorder that may occur after mastectomies, when tissue is removed from the upper outer quadrant of the breast or axilla, where major nerves are vulnerable to nerve injury [3,4]

Read more

Summary

Introduction

The use of opioids in mastectomy patients is a particular challenge, having to balance the management of acute pain while minimizing risks of continuous opioid use postoperatively. Chronic pain is one of the most common complications of breast surgery, estimated to affect 20-30% of patients [2]. Postmastectomy pain syndrome (PMPS) is a type of chronic neuropathic pain disorder that may occur after mastectomies, when tissue is removed from the upper outer quadrant of the breast or axilla, where major nerves are vulnerable to nerve injury [3,4]. PMPS can be severe enough to cause long-term disabilities, interfering with sleep and performance of daily activities [6]. Retrospective studies found that PMPS can cause persistent stress that can increase an individual’s susceptibility to stress-related physical and mental health problems [6]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call